CSL Of Australia To Begin Trials Of H1N1 Flu Vaccine On Children
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL said it would begin clinical trials next week on a pediatric version of its H1N1 flu virus, one recommended for use down to the age of six months. The trials are intended to determine the best dosage for children. Children are considered the most susceptible to the virus and in turn spread the infection, particularly to people with poor immune systems. (Click here for more